|
Synonyms: TRL1068
Compound class:
Antibody
Comment: Calpurbatug is a fully human monoclonal antibody against members of the DNABII family of bacterial DNA-binding proteins [1-2]. It disrupts bacterial biofilms and is being developed by Trellis Bioscience as a potential treatment in prosthetic joint infections and in chronic rhinosinusitis.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
| No information available. |
Summary of Clinical Use  |
| Calpurbatug is being evaluated in Phase 1 clinical trial in patients with prosthetic joint infections (NCT04763759) or with chronic rhinosinusitis (NCT05355207). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04763759 | Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections | Phase 1 Interventional | Trellis Bioscience LLC | ||
| NCT05355207 | Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis | Phase 1 Interventional | Trellis Bioscience LLC | ||
